fingolimod fmk 0,5 mg tvrdé kapsuly
farmak international sp. z o.o., poľsko - fingolimod - 59 - immunopraeparata
jayempi
nova laboratories ireland limited - azathioprine - odmietnutie štepu - imunosupresíva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
ponvory
janssen-cilag international n.v. - ponesimod - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
fingolimod mylan
mylan ireland limited - fingolimod hydrochlorid - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1)orpatients s rýchlo sa meniacim ťažké recidivujúce odosielajúcej roztrúsená skleróza definovaná 2 alebo viac vypnutie relapsami v jednom roku, a s 1 alebo viac gadolínium zvýšenie lézie v mozgu mri alebo významný nárast v t2 lézií zaťažení v porovnaní s predchádzajúcim posledných mri.
inzolfi 0,5 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - fingolimod - 59 - immunopraeparata
fingolimod mylan
mylan ireland limited - fingolimod hydrochlorid - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
gaxenim 0,5 mg
bausch health ireland limited , Írsko - fingolimod - 59 - immunopraeparata
fingolimod richter 0,5 mg tvrdé kapsuly
gedeon richter plc., maďarsko - fingolimod - 59 - immunopraeparata
aciclovir noridem 500 mg prášok na infúzny roztok
noridem enterprises ltd., cyprus - aciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)
aciclovir noridem 250 mg prášok na infúzny roztok
noridem enterprises ltd., cyprus - aciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)